Revolution Medicines, Inc. RVMD EBITDA margin
EBITDA margin at other companies
Other financials
Where this comes from
Calculated from Revolution Medicines, Inc.’s reported figures.
Based on trailing twelve months.
The official record: Revolution Medicines, Inc.’s 10-Q, filed November 5, 2025, on SEC EDGAR. View the filing →
Ask your AI about Revolution Medicines, Inc.'s ebitda margin.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Revolution Medicines, Inc.'s EBITDA margin?
- Revolution Medicines, Inc. (RVMD) reported EBITDA margin of -87,211.9% in Q3 2024.
- How has Revolution Medicines, Inc.'s EBITDA margin changed year-over-year?
- Revolution Medicines, Inc.'s EBITDA margin decreased by 6168.4% year-over-year, from -1,391.3% to -87,211.9%.
- What is the long-term trend for Revolution Medicines, Inc.'s EBITDA margin?
- Over 2 years (2021 to 2023), Revolution Medicines, Inc.'s EBITDA margin has grown at a 99.7% compound annual growth rate (CAGR), from -1,857.8% to -7,410.5%.
- What does EBITDA margin mean?
- Operating cash profitability per sales dollar, before interest, taxes, and non-cash charges.
- How do you interpret EBITDA margin?
- Useful for comparing operating profitability across firms with different depreciation policies and leverage. High EBITDA margin alongside heavy capex can still mean weak free cash flow — pair it with FCF margin.
- How does EBITDA margin compare across companies?
- Widely used to compare capital-intensive businesses on a like-for-like basis. Less meaningful for banks and insurers.